Please login to the form below

Not currently logged in
Email:
Password:

EC consults on orphan drug application guidelines

Also seeks input on the transfer of designations from one sponsor to another

The European Commission (EC) has put its proposed guideline on the format and content of applications for orphan drug status out to public consultation.

The proposed guideline provides supplementary advice on how to compile the documents that should be provided by sponsors in an application for orphan medicinal product designation

It also covers the provision of advice to sponsors wishing to transfer the designation of an orphan medicinal product and/or to change the name or address of a sponsor.

• Comments and suggestions are invited by September, 30 and should emailed to: sanco-pharmaceuticals-d5@ec.europa.eu

19th July 2013

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...
Overcoming the digital patient recruitment challenges of connecting with patients
How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...